Navigation Links
NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
Date:4/8/2013

ny also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers.  The Company also conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania. 

DisclaimerStatements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future eve
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies
2. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
3. Susan Cain Will Kick Off 2013 ASAE Annual Meeting & Exposition, Dan Heath is Closing General Session Speaker
4. Electronic Headband That Detects and Treats Addictive In-Sleep Behavior to be Demonstrated at Annual Holistic Dental Conference by Holistic Technologies
5. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
6. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
7. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
8. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
9. Archimedes Inc. Renews Annual Marketing Agreement with HealthEconomics.Com
10. Palatin Technologies To Present At The 25th Annual ROTH Conference
11. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... ... Strong Animals™ announced today that research conducted by South Dakota State University ... Joint Annual Meeting held July 12-16 in Orlando, FL showed feed additive Stay Strong™ ... Also, feed containing Stay Strong™ for Dairy Cows took longer than 7.7 hours before ...
(Date:7/28/2015)... 2015 People with a common form of ... and sometimes profound improvements in their hearing and understanding ... a new multicenter study led by specialists at NYU ... online ahead of print in the journal The Laryngoscope July ... in the United States implanted ...
(Date:7/28/2015)... DUBLIN , July 21, 2015 ... ) has announced the addition of the ... report to their offering. Globally, ... applications including immuno-phenotyping, cell proliferation, cancer, and stem ... in clinical applications primarily because of demand from ...
(Date:7/28/2015)... , July 28, 2015 Deerfield Management Company, ... Innovations Fund, L.P., which will invest in groundbreaking advancements ... genetic diseases, cancer, and orphan diseases. The venture capital ... how therapeutics are developed and improve the way healthcare ... of the largest healthcare-focused venture funds in the sector, ...
Breaking Biology Technology:Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3
... with Josh Heling, co-founder, SecurePipe, Inc. SecurePipe ... of industries including manufacturing, healthcare, banking, environmental response, consumer ... engineering, raising money, and ecruiting a CEO. , , ... little about SecurePipe. , , Josh Heling (JH): ...
... common to talk about the long road from recession to recovery ... quickly. This wasnt going to be couldnt be --- rushed. ... to look like the race might actually have a finish line. ... are falling. Earnings reports are holding steady. In recent weeks, a ...
... led by Governor Doyle and organized by Forward Wisconsin ... industrys leading conference with goals to establish new partnerships, ... community and to let others know that Wisconsin has ... group, the delegation met its objectives in spite of ...
Cached Biology Technology:WTN Exclusive Interview with Josh Heling 2WTN Exclusive Interview with Josh Heling 3The End is Near or Is It? 2The End is Near or Is It? 3The End is Near or Is It? 4On site at BIO 2003 2On site at BIO 2003 3On site at BIO 2003 4On site at BIO 2003 5
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... RAPID CITY, S.D. Anna Balazs, a pioneer in ... materials through her theoretical predictions, has been named 2013 ... & Technology. Balazs, Ph.D., is Distinguished Professor of ... of expertise is theoretical and computational modeling of polymer ...
... a global life sciences technology company specializing in clinical study ... exhibiting the company,s entire suite of eClinical technologies , ... , at the upcoming Summit for Clinical Ops Executives (SCOPE) ... Hyatt Regency Miami in Miami , Florida.  ...
... of Houston faculty members have been named Charter Fellows ... outstanding contributions to scientific and technological innovation. UH ... engineering, Paul Chu, a physics professor and chief scientist ... and Dan Luss, a professor in chemical and biomedical ...
Cached Biology News:Anna Balazs announced as 2013 Mines Medalist 2Anna Balazs announced as 2013 Mines Medalist 3MedNet Solutions To Feature iMedNet EDC At The 2013 SCOPE Conference 2National Academy of Inventors honors 3 University of Houston professors 2National Academy of Inventors honors 3 University of Houston professors 3
Request Info...
Peptide Sequence: ovine COX-1 amino acids 272-282 (LMHYPRGIPPQ) To be used in conjunction with Cayman's COX-1 (ovine) polyclonal antiserum (Catalog No. 160108) to block protein-antibody complex f...
Anti-human VEGFR-1/Flt-1, clone Flt-1/EWI, Monoclonal Antibody...
Request Info...
Biology Products: